Aim The aim of this study was to assess the predictive role of fluorine-18-fluorodeoxyglucose
(18 F-FDG) PET/computed tomography (CT) in the evaluation of response to immunotherapy …

Background Immune checkpoint inhibitors (ICIs) have become a high-profile regimen for
malignancy recently. However, only a small subpopulation obtains long-term clinical benefit …

Background This study aimed to determine the relationship of programmed death-ligand 1
(PD-L1) expression and standardized uptake values in fluorodeoxyglucose–positron …

Combined chemotherapy plus programmed death-1 (PD-1) blockade is an established
treatment against patients with advanced non–small cell lung cancer (NSCLC). However, a …

337 Objectives The immune checkpoint, programmed cell death protein-1/programmed cell
death ligand-1 (PD-1/PD-L1) pathway has emerged as a critical target for cancer …

239 Introduction: The recent rise of checkpoint inhibitor therapy, predominantly programmed
cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies as a standard care of …

Abstract Background Programmed death-ligand-1 (PD-L1) is a well-known predictive
biomarker in non-small cell lung cancer (NSCLC) patients, however, its accuracy remains …

Objective The aim of this study is to evaluate correlation between Programmed cell death
ligand 1 (PD-L1) mutation status with metabolic parameters derived from 18-F Fluoro-2 …

Programmed cell death ligand 1 (PD-L1) is a critical biomarker for predicting the response to
immunotherapy. However, traditional quantitative evaluation of PD-L1 expression using …

Lung cancer is a malignant tumour originating from the bronchial epithelium or glands of the
lung with high morbidity and mortality. For advanced lung cancer, the lack of effective …